Clinical Experience with Linezolid for the Treatment of Nocardia Infection

Moylett, Edina H.; Pacheco, Susan E.; Brown-Elliott, Barbara A.; Perry, Tracy R.; Buescher, Stephen; Birmingham, Mary C.; Schentag, Jerome J.; Gimbel, Joseph F.; Apodaca, Aaron; Schwartz, Margot A.; Rakita, Robert M.; Wallace Jr., Richard J.
February 2003
Clinical Infectious Diseases;2/1/2003, Vol. 36 Issue 3, p313
Academic Journal
Linezolid is an oxazolidinone that has activity against most gram-positive bacteria, including in vitro activity against all Nocardia species and strains. We describe 6 clinical cases of nocardiosis that were successfully treated with linezolid. Two patients had underlying X-linked chronic granulomatous disease, and 2 patients were receiving chronic corticosteroid therapy. Four of 6 patients had disseminated disease, and 2 of these 4 patients had multiple brain abscesses. Four patients primarily received monotherapy; for the fifth patient, linezolid was added to a failing multiple-drug regimen, and, for the sixth patient, it was used as part of combination therapy. All 6 patients were successfully treated, although 1 patient had a presumed relapse of central nervous system infection after premature discontinuation of the drug. Linezolid appears to be an effective alternative for the treatment of nocardiosis.


Related Articles

  • Reward Drug Firms for Reducing Resistance.  // USA Today Magazine;Oct2010, Vol. 139 Issue 2785, p11 

    The article reports on the challenges facing pharmaceutical companies and the public health sector in the U.S. regarding the use of antibacterial drugs for the rising rates of antibiotic-resistant infections.

  • Linezolid: A Review of its Use in the Management of Serious Gram-Positive Infections. Perry, C.M.; Jarvis, B. // Drugs;Feb2001, Vol. 61 Issue 4, p525 

    Linezolid is the first of a new class of antibacterial drugs, the oxazolidinones. It has inhibitory activity against a broad range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-intermediate S. aureus (GISA), vancomycin-resistant enterococci...

  • Today's strategies for bacterial skin infections. Turbo, Richard // Patient Care;3/30/1997, Vol. 31 Issue 6, p78 

    Focuses on the management of several bacterial skin infections. Pathogenic organisms of different primary bacterial infections; Complications; Systemic symptoms; Commonly prescribed antibiotics; Common contributors to secondary infections. INSETS: The dangers of `superficial' skin...

  • Two new once-daily quinolones for pneumonia and bronchitis.  // Modern Medicine;Feb97, Vol. 65 Issue 2, p35 

    Reports on the availability of quinolone agents sparfloxacin and levofloxacin for the treatment of adults who have infections caused by susceptible strains of designated microorganisms. Indications; Recommended dosage.

  • Are we under-estimating basic first line drug regimes of beta-lactam antibiotics clindamycin and metronidazole in dental oral and maxillofacial infections?  // Annals of Maxillofacial Surgery;Jan-Jun2013, Vol. 3 Issue 1, p104 

    A letter to the editor is presented about basic first line drug regimes of beta-lactam antibiotics clindamycin and metronidazole in dental oral and maxillofacial infections.

  • Ketolides: A New Class of Antibacterial Agents for Treatment of Community-Acquired Respiratory Tract Infections in a Primary Care Setting. Clark, Jeffrey Paul; Langston, Edward // Mayo Clinic Proceedings;Sep2003, Vol. 78 Issue 9, p1113 

    Examines the use of telithromycin ketolide antibacterial agent to treat community-acquired respiratory tract infections. Drug activity against respiratory pathogens; Drug effectiveness and safety; Drug tolerance; Drug interaction potential.

  • Ciproxin.  // Royal Society of Medicine: Medicines;2002, p156 

    The article presents information on Ciproxin, a proprietary, prescription-only preparation of the antibiotic-like antibacterial ciprofloxacin. It can be used to treat a variety of infections, for example, of the urinary tract and gonorrhoea. It is available as tablets, a suspension and in a form...

  • UTIs: Consider short-course quinolone in older women.  // Geriatrics;Mar97, Vol. 52 Issue 3, p85 

    Presents an abstract of the article `3-day Course of Ofloxacin Versus Cefalexin in the Treatment of Urinary Tract Infections in Postmenopausal Women,' by R. Raz and S. Rozenfeld in `Antimicrobial Agents and Chemotherapy' dated 1996.

  • New help for urinary tract infections. Zamula, Evelyn // FDA Consumer;Jun95, Vol. 29 Issue 5, p15 

    Deals with the prevalence of urinary tract infection (UTI) among women and the development of drugs to treat both uncomplicated UTIs and more serious ones. Food and Drug Administration's approval of a group of drugs called quinolones; Symptoms of infections; Escherichia coli infections; Role of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics